Update on Glaxo's Portfolio - Analyst Blog

By
A A A

Over the last few months, quite a few drugs at GlaxoSmithKline ( GSK ) have gained approval including Breo Ellipta (chronic obstructive pulmonary disorder/COPD), Tafinlar and Mekinist (both melanoma), and Tivicay (HIV).

Glaxo is also working on expanding the labels of some of its existing products. Last month, the European Commission (EC) approved Tyverb in combination with Roche 's ( RHHBY ) Herceptin for the treatment of patients with metastatic HER2 positive breast cancer who have received prior Herceptin therapy.

The EC has also approved Revolade for an additional indication, the treatment of thrombocytopenia (reduced platelet count) in adults with chronic hepatitis C virus (HCV) infection to enable the initiation of interferon-based therapy and achieve optimum results. Interferon-based therapies are commonly prescribed treatments for chronic HCV infection. We note that chronic HCV infection can cause several blood-related disorders including thrombocytopenia.

The approval came in on the basis of encouraging safety and efficacy data from two randomized, double-blind, placebo controlled and multi-center phase III studies, which enrolled approximately 1,520 patients.

We remind investors that the U.S. Food and Drug Administration (FDA) has already approved the drug (marketed as Promacta) in the U.S. for the above mentioned indication in Nov 2012.

Promacta is also approved for idiopathic thrombocytopenic purpura, in both the U.S. and EU. Glaxo has a research & collaboration agreement with Ligand Pharmaceuticals Inc. ( LGND ) for this drug.

Promacta sales came in at £45 million in the second quarter of 2013, up 53% from the year-ago period. We are pleased with Glaxo's label expansion efforts, which should boost sales further.

Glaxo, a large cap pharma stock, presently carries a Zacks Rank #3 (Hold). However,  other large cap pharma stocks like Eli Lilly and Company ( LLY ) and Roche currently look better positioned with a Zacks Rank #2 (Buy) and a Zacks Rank #1 (Strong Buy), respectively.



GLAXOSMITHKLINE (GSK): Free Stock Analysis Report

LIGAND PHARMA-B (LGND): Free Stock Analysis Report

LILLY ELI & CO (LLY): Free Stock Analysis Report

ROCHE HLDG LTD (RHHBY): Get Free Report

To read this article on Zacks.com click here.

Zacks Investment Research



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Business , Stocks

Referenced Stocks: EC , GSK , LGND , LLY , RHHBY

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Stocks

Referenced

100%
80%
50%
100%

Most Active by Volume

61,354,178
  • $10.59 ▲ 13.26%
57,732,182
  • $16.27 ▲ 1.12%
51,991,548
  • $103.30 ▲ 0.78%
48,129,834
  • $20.65 ▲ 5.52%
41,623,916
  • $12.63 ▲ 8.13%
34,295,241
  • $76.68 ▲ 2.49%
31,519,079
  • $34.57 ▼ 1.00%
28,847,879
  • $3.64 ▲ 0.28%
As of 9/2/2014, 04:15 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com